Inhibition of specific Akt isoforms in CD8+ T cells promotes favored differentiation into memory versus effector cells, the former of which are superior in mediating anti-tumor immunity. In this study, we investigated the role of upstream PI3K isoforms in CD8+ T cell differentiation and assessed the potential use of PI3K isoform-specific inhibitors to favorably condition CD8+ T cells for adoptive cell therapy. The phenotype and proliferative ability of tumor antigen specific CD8+ T cells was assessed in the presence of PI3K-α, -β, or -δ inhibitors.
Introduction
CD8+ T-cell response comprises effector and memory T-cells (1, 2) . Memory T-cells possess enhanced proliferative ability, greater functionality and better longevity than effector cells.
Different subsets of CD8 memory T-cells including effector (T EM ) and central (T CM ) memory Tcells represent different stages of the CD8 differentiation spectrum (2, 3) . T CM are an earlier stage of differentiation and therefore possess superior qualities enabling them to better fight microbial challenges and mediate therapeutic antitumor immunity when compared to T EM , which in turn are superior to the terminally differentiated effector cells (4) (5) (6) (7) .
The differentiation of T-cell is under the control of the PI3K/Akt pathway (1) . Akt activation was found to regulate the effector/memory CD8+ T-cell differentiation (8) . In fact, Akt inhibition was reported to augment anti-tumor immune responses by enhancing the expansion of CD8+ Tcells with memory characteristics (9) . Also, we have reported that inhibition of specific Akt isoforms, Akt1 and Akt2, delays the terminal differentiation of CD8+ T-cells while enhancing the T CM phenotype. Targeting these specific Akt isoforms therefore enhanced the proliferative ability, longevity and cytokine production in CD8+ T-cells (10) We therefore investigated the potential role of specific upstream PI3K isoforms in the regulation of the CD8+ T-cell differentiation with the aim of exploring the potential use of specific PI3K isoforms inhibitors to condition CD8+ T-cells for adoptive cell transfer for better therapeutic outcome.
We found that the inhibition of only PI3K-δ, but not PI3K-α or PI3K-β, delays the terminal differentiation of CD8+ T-cell and maintains the memory phenotype thus enhancing their proliferative ability and survival while maintaining their cytokine and Granzyme B production Author Manuscript Published OnlineFirst on June 14, 2017; DOI: 10.1158/0008-5472. CAN-16-1925 ability. We further demonstrated the ex-vivo PI3K-δ inhibition enhances anti-tumor therapeutic ability of adoptively transferred CD8+ T-cells in animal models compared to non-treated CD8+ T-cells.
In cancer immunotherapy, it is important to maintain a CD8 that is antigen specific, highly cytotoxic, renewable, highly proliferative and in earlier stages of differentiation to delay exhaustion. Here, we report that ex-vivo inhibition of a single isoform, PI3K-δ, in CD8+ T-cells enhances their proliferation, cytokine production and subsequently their anti-tumor therapeutic ability and delays their exhaustion.
This discovery has important clinical implications. Recently, clinical trials using the PI3K-δ inhibitor Idelalisib (Zydelig, CAL-101) to treat malignancies were put on hold (11) and new guidelines for its prescription were introduced. This was due to the increased number of deaths in the Idelalisib (Zydelig, CAL-101) group which were mainly attributed to infections by P jirovecii and cytomegalovirus, in addition to respiratory events possibly caused by infection (12). Our discovery provides a plausible explanation, where the use of PI3K-δ inhibitors delays the later stages of CD8 differentiation, which are thought to be the most potent against opportunistic viral infections. Hence their systematic administration deprives the body of the most potent anti-viral CD8+ T-cells.
Our findings suggest a strategy that enhances the anti-tumor therapeutic efficiency of adoptive cell transfer while avoiding the adverse effects of the systemic administration of PI3K-δ inhibitors. We show that ex-vivo PI3K-δ inhibition delays terminal differentiation, maintains memory phenotypes, prolongs the life span and enhances the expansion of tumor specific CD8+
T-cells without affecting their cytotoxic activity. This translates into an enhanced in vivo antitumor therapeutic ability and therefore holds great clinical implications for the use of these 
Materials and Methods

Mice and reagents
pMel-1 mice (B6.Cg-Thy1 a /Cy Tg(TcraTcrb)8Rest/J) used for in vitro experiments carry a rearranged T-cell receptor transgene (Vβ13) specific for gp100 (13) . For feeder cells and in vitro experiments, female C57BL/6(H-2b) wild-type (WT) mice were used. For in vivo experiments, 4-6 week old WT female mice were used. (Mice were purchased from Jackson Laboratory and housed under pathogen-free conditions according. All procedures were carried out in accordance with Institutional Animal Care and Use Committee (IACUC).
B16 cell line was purchased from American Type Culture Collection (ATCC) (Manassas, VA) which routinely authenticate and test cell lines (for mycoplasma, by the Hoechst stain, PCR and the standard culture test). These cells were used in experiments after two to three passages from thawing (between 2014 and 2015). B16 was authenticated and tested for mouse parvovirus (MPV) and mouse hepatitis virus (MHV) using PCR at Augusta University. All tests were negative.
Inhibitors were purchased from Selleckchem. GDC-0941 is a pan PI3K inhibitor with IC50 of 3nM for p110α, 33nM for p110β, 3nM for p110δ and 75nM for p110γ. GDC-0941 was used in vitro at 11, 33, 99 and 279nM concentrations, ensuring inhibition of all three Class 1isoforms.
A66 is a selective p110α inhibitor with IC50 of 32nM for the p110α, 236nM for PI4Kβ, 462nM
for C2β and >1.25μM for p110δ. A66 was used in vitro at 32, 96 and 288nM concentrations, ensuring selectivity to PI3Kα. TGX-221 is a highly selective PI3Kβinhibitor with IC50 of 5μM for p110α, 5nM for p100β, 0.1μM for p100δ and > 10μM for p110γ. In in vitro experiments, TGX-221 was used at 5, 15 and 45nM to ensure selectivity. CAL-101 is a selective PI3Kδ   inhibitor with IC50 of 820nM for p110α, 565nM for p110β, 2.5nM for p110δ and 89nM for p110γ. This inhibitor was tested in vitro at 0.28, 0.83, 2.5, 7.5, 22.5, 67.5,and 202.5nM to maximize the drug's specificity.
The gp100 25-33 9-mer peptide (KVPRNQDWL) (ANASPEC) was used for in vitro activation of pMel-1 splenocytes at 1µM as described (10) .
For in vivo experiments, the vaccine was prepared using the same gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] peptide and administered at 100µg per mouse in combination with PADRE at 10µg and Quil-A at 25µg per mouse.
Lymphodepletetion of mice was achieved using a combination of 250mg/kg cyclophosphamide (Sigma) and 50mg/kg fludarabine (Selleckchem).
In vitro activation of CD8+ T-cells
Tumor antigen-specific CD8+ T-cells CD8+ T-cells from pMel-1 mice were activated in vitro as described (10) . Briefly, homogenized pMel-1 splenocytes were stimulated with gp100 25-33 peptide at 1µM (day 0). Cells were cultured in RPMI-1640 (Lonza) supplemented with 10% FBS, penicillin (100 U/mL), streptomycin (100 mg/mL), 0.1% β-mercaptoethanol (Life Technologies, Invitrogen) and IL-2 (100U/ml) (Peprotech) at 37ᵒC with 5% CO2. pMel-1 cells were cultured with or without different PI3K
inhibitors. The concentration of the inhibitors was maintained throughout the culture by changing the media every 48-72 hours. On Days 7, 14 and 21, cells were re-stimulated with gp100 25-33 at 1µM using feeder cells (irradiated WT splenocytes, 4000 Rads) at 1:1 ratio using the same culture conditions.
TCR stimulation and co-stimulation
Viable CD8+ T-cells from WT mice were sorted using FACS ARIA II (BD Biosciences; purity > 99%). Cells were activated on anti-CD3-coated plates (10ug/ml) and cultured in activation media (IL2 (100U/ml) and anti-CD28 (2.5ug/ml)) in the presence or absence of PI3K inhibitors for 72 hrs. 
Proliferation assay and phenotyping of CD8+ T-cells
Cytometric bead array
Using the stimulation protocol above, CD8+ T-cells were harvested on day 7 after the first and second stimulation. Viable (trypan blue negative) cells were co-incubated (at 1:1 ratio) with 1µM gp100 25-33 pulsated irradiated splenocytes (4000 Rads) for 24 hours using the same culture conditions. Supernatants were collected and the level of IL-2, TNF-α and IFN-γ was assessed using the mouse Th1/Th2/Th17 Cytokine Kit BD™ Cytometric Bead Array (CBA) kit. Cytokine levels were collected using an LSRII SORP with HTS flow cytometer (BD Biosciences), and analyzed using the FCAP Array Software v3.0 (BD Biosciences).
In Vivo tumor treatment
C57BL/6 female mice were implanted with 400,000 B16 cells/mouse subcutaneously (s.c.) in the right flank on day 0 (B16 expresses gp100 antigen). On day 7, mice were lymphodepleted by s.c. Author Manuscript Published OnlineFirst on June 14, 2017; DOI: 10.1158/0008-5472. CAN-16-1925 which is a marker associated with memory phenotype and with high proliferative potential ( Figure 1C ).
We next measured IL-2 secretion in CD8+ T-cells,, a property that is diminished in terminally differentiated CD8+ T-cells. We found that CD8+ T-cells treated with GDC maintained a significantly high level of IL-2 secretion after re-encountering the antigen ( Figure 1D ).
Taken together, these data show that PI3K inhibition preserves the memory phenotype in antigen stimulated CD8+ T-cells, hence enhancing the proliferative potential and survival while delaying the terminal differentiation of these CD8+ T-cells.
PI3K inhibition does not affect the ability of CD8+ T-cells to produce cytotoxic cytokines and Granzyme B
We have demonstrated that PI3K inhibition enhances proliferation of CD8+ T-cells, preserves the T CM phenotype and delays terminal differentiation. Classically, effector functions were thought to peak at the effector state (2), however, more recent findings suggest that memory cells are superior in their cytotoxic abilities because of memory recall and proliferation potential, and therefore are superior options for ACT (7, 10, 16) . To assess whether the function of the resultant T CM cells is affected by the inhibition of PI3K, we measured their ability to secrete IFN-γ and TNF-α and the level of Granzyme B production.
CD8+ T-cells were re-stimulated on days 7 and 14 (stim2 and 3) and the level of IFN-γ and TNF-α production after 24 hours was assessed. After the second and third stimulations, GDCtreated and non-treated cells produced high and comparable levels of IFN-γ and TNF-α in response to antigen re-encounter ( Figure 1D ). CAN-16-1925 To further test the cytotoxic ability of the CD8+ T-cells treated with PI3K inhibitor, we assessed the level of Granzyme B production by intracellular staining. As shown below, following the first and second stimulations, we found that the inhibition of PI3K does not affect the production of Granzyme B when compared to CD8+ T-cell that were not treated with PI3K inhibitors .
The maintained levels of IFN-γ and TNF-α secretion and Granzyme B production suggest that CD8+ T-cells treated with PI3K inhibitors maintain their cytotoxic functionality. Added to the marked increase in their proliferation potential and their enhanced survival, CD8+ T-cells treated with PI3K inhibitors are potentially a superior option for ACT.
PI3K-δ is the isoform responsible for terminal differentiation of CD8+ T-cells
We have shown that PI3K inhibition in CD8+ T-cells delays their terminal differentiation, preserves T CM cells, enhances their proliferative ability while maintaining their cytokine secretion ability and prolonging their survival. The role of specific PI3K isoforms (PI3K-α, PI3K-β and PI3K-δ) in the development, proliferation and function of CD8+ T-cells is not known. Using selective PI3K inhibitors, we next tested whether the inhibition of a single PI3K isoform would be sufficient to delay terminal differentiation of CD8.
When the phenotype of the cells was assessed after 3 days of the first stimulation, CD8+ T-cells treated with inhibitors specific for PI3K-α (A66) or PI3K-β (TGX-221), there were no differences in the phenotype of CD8+ T-cells from the non-treated cells (Figure 2A) . However, only when the PI3K-δ inhibitor (CAL-101) was used, CD8+ T-cells displayed a phenotype similar to that observed with pan PI3K inhibition, where there was a higher percentage of T CM cells when compared to non-treated cells (Figure 2A and Supplemental Figure 1 ). As expected, due to memory recall, this effect was less prominent after the second and third stimulations when Figure 3A) . Furthermore, the proliferation of CD8+ T-cells and their ability to produce Granzyme B was not affected by the knock down of any of the isoforms (Supplemental Figure 3A) . These findings were replicated in human CD8+ T-cells, where the stimulation of purified human CD8+ T-cells from healthy human donors in the presence of the pan PI3K inhibitor GDC resulted in maintaining a high level of CD62L without affecting the proliferation of the cells (Supplemental Figure 3B) . Furthermore, the inhibition of PI3K-δ in activated human CD8+ Tcells resulted in the maintenance of a high expression level of CD62L which was not observed when PI3K-α or -β were inhibited (Supplemental Figure 3B) .
Taken together, our data demonstrate that PI3K-δ is responsible for the terminal differentiation of CD8 and the inhibition of PI3K-δ, but not PI3K-α or PI3K-β, preserves CD8+ T-cells in memory state, thus enhancing their proliferative potential, longevity, and survival without affecting their ability to produce cytokines and Granzyme B.
The inhibition of PI3K-δ in CD8+ T-cells significantly enhances their anti-tumor therapeutic ability in vivo
We have shown that PI3K-δ inhibition delays the terminal differentiation of CD8+ T-cells and enhances their proliferative ability and survival without affecting their ability to produce cytokines and Granzyme B. To test if these findings translate into enhanced therapeutic ability in vivo, we adoptively transferred tumor antigen specific CD8+ T-cells treated with CAL-101 into CD8+ T-cells treated specifically with an inhibitor of PI3K-δ greatly enhance their anti-tumor therapeutic ability when adoptively transferred into tumor bearing mice.
As CD8+ T-cells differentiate from naïve to effector cells, they lose their ability to produce IL-2 (3). Here, we further show that PI3K-δ inhibition maintains a higher level of IL-2 secretion in CD8+ T-cells. Additionally, we show that the inhibition of PI3K-δ maintains a high level of CD62L which is in agreement with the findings of Sinclair et al (2008) who showed that the proteolysis of CD62L is controlled by PI3K-δ (20) . Classically, cytotoxic effector functions were thought to gradually increase from naïve through memory and peak at the effector state (2), however more recent reports suggest that memory cells are superior in their cytotoxic abilities (7, 10, 16) . This is in agreement with our findings, where PI3K-δ inhibition enhances the proliferative ability and longevity of CD8+ T-cells without affecting their cytotoxic functionality. We found that the inhibition of the PI3K-δ also does not affect the CD8+ T-cells' ability to secrete TNF, IFNγ and Granzyme B. Based on above, it is clear that treatment of CD8+ T-cells with PI3K-δ provides a superior quality T cells for more effective ACT.
Here we further demonstrate that our in vitro findings translated to in-vivo application where treating tumor specific CD8+ T-cells with PI3K-δ inhibitor greatly enhances their anti-tumor ability when adoptively transferred into tumor bearing mice. This is not surprising given the enhanced proliferation, survival and functionality of inhibitor treated cells in vitro. Furthermore, we also found that the therapeutic ability of these cells was greatly enhanced with the combination of a tumor specific vaccine since memory CD8+ T-cells respond to antigen reencounter by proliferating more robustly than exhausted effector CD8+ T-cells. Thus, the preservation of memory cells using only PI3K-δ inhibition produces an enhanced cytotoxic anti- CAN-16-1925 tumor ability. This was demonstrated by a significant slowdown of tumor growth and a significant enhancement of animal survival.
Interestingly, we found that CD8+ T-cell differentiation is controlled specifically through the PI3K-δ isoform that signals downstream through Akt1 and Akt2, the two Akt isoforms we had already shown to be responsible for the differentiation of CD8+ T cells (10) . We also found that in CD8+ T cells, PI3K-α and PI3K-β play no role in proliferation and survival and that these two isoforms do not signal through Akt1 and Akt2 (Supplemental Figure 5) . Accordingly, PI3K-δ is the only isoform that controls these biologic functions in CD8+ T-cells. A) The ability of CD8+ T-cells to produce IFNγ and TNF-α was not affected by the inhibition of specific PI3K isoforms.
B) The ability of CD8+ T-cells to produce Granzyme B was not affected by PI3K inhibition. 
